Related Articles
Unknown‑primary neuroendocrine neoplasms diagnosed by short‑acting somatostatin test: Case series in one institution
Somatostatin receptor expression indicates improved prognosis in gastroenteropancreatic neuroendocrine neoplasm, and octreotide long‑acting release is effective and safe in Chinese patients with advanced gastroenteropancreatic neuroendocrine tumors
Effective treatment of H838 human non-small cell lung carcinoma with a targeted cytotoxic somatostatin analog, AN-238
Treatment of hepatocellular carcinoma with long acting somatostatin analogues
Somatostatin receptor subtypes 2 and 5 are associated with better survival in operable hepatitis B‑related hepatocellular carcinoma following octreotide long‑acting release treatment